Navigation Links
BioSpecifics Announces Partnership Between Auxilium and Actelion for XIAFLEX® in Canada, Australia, Brazil and Mexico
Date:2/23/2012

LYNBROOK, N.Y., Feb. 23, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced that its partner Auxilium Pharmaceuticals, Inc. (Auxilium) has entered into a partnership with Actelion Pharmaceuticals Ltd. (Actelion) for the long-term development, supply and commercialization of XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's disease. Under this agreement, Actelion will receive exclusive rights to commercialize XIAFLEX for the two indications in Canada, Australia, Brazil and Mexico upon receipt of the respective regulatory approvals. Actelion will be primarily responsible for the applicable regulatory and commercialization activities for XIAFLEX in these countries.

"We are excited to announce this strategic collaboration with Actelion, which will further enable XIAFLEX to reach patients around the world who are in need of this treatment," reflected Thomas L. Wegman, President of BioSpecifics. "XIAFLEX is already available in the U.S. and nine European and Eurasian markets for patients with Dupuytren's contracture and we look forward to potential additional approvals in these new partnership territories, as well as reporting top-line results from Auxilium's global Phase III study of XIAFLEX for Peyronie's disease by the end of the second quarter of this year. This lead pipeline indication has the potential to greatly increase the market for injectable collagenase due to the devastating effects of this disease."

BioSpecifics will receive a certain percentage of the $10 million upfront payment paid to Auxilium from Actelion as well as a certain percentage of the up to $16 million in potential regulatory, pricing and reimbursement milestone payments and $42.5 mil
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioSpecifics Technologies Corp. to Present at Lazard Capital Markets 8th Annual Healthcare Conference
2. Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX®
3. BioSpecifics Technologies Corp. Reports Second Quarter 2011 Financial Results
4. BioSpecifics Technologies Corp. Announces Board Authorization of up to $2 Million Share Repurchase Program
5. BioSpecifics Technologies Corp. to Present at Jefferies 2011 Global Healthcare Conference
6. BioSpecifics Announces Positive XIAPEX® Data Presented at XVI Annual Federation of European Societies for Surgery of the Hand Congress
7. BioSpecifics Technologies Corp. Provides Update on XIAPEX® Launch Progress in EU
8. BioSpecifics Technologies Corp. to Present at SEVEN, Noble Financial Capital Markets Seventh Annual Equity Conference
9. BioSpecifics Technologies Corp. Announces Launch of XIAPEX® by Pfizer for Treatment of Dupuytrens Contracture in Europe
10. BioSpecifics Technologies Corp. to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference
11. BioSpecifics Technologies Corp. Amends Its Rights Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  Quantum Materials Corporation ... sets of patent families from Bayer Technology Services GmbH, ... for Bayer AG of Leverkusen, Germany ... provide broad intellectual property protection for advances ... quantum dot (QD) manufacturing. In addition, the Bayer ...
(Date:8/20/2014)... Glenmark Pharmaceuticals S.A. (GPSA), ... India (GPL), announces the discovery and initiation of ... candidate, GBR 1302, a HER2xCD3 bispecific antibody. GBR ... Biologics Research Centre located in La Chaux-de-Fonds, ... on Glenmark,s innovative BEAT antibody technology platform which ...
(Date:8/20/2014)... 20, 2014 Phase I Trial ... US  KalVista Pharmaceuticals ("KalVista"), an ophthalmology company ... announces that it has begun a Phase I, First ... KVD001, for the treatment of DME. The study,s Principal ... Eye Institute, Joslin Diabetes Center; Harvard Medical School Department ...
Breaking Medicine Technology:Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... Information Systems ("SIS"), a leader in perioperative ... leadership in achieving clinical, financial, and operational goals ... the company,s annual client conference, the 2012 SIS ... systems exemplifying the innovative use of information technology ...
... 2012 Top leaders representing America,s advanced medical ... public policy issues affecting job creation and medical innovation and ... billion medical device tax set to begin in January 2013. ... Renacci (R-Ohio) joined Walter M Rosebrough, president and CEO of ...
Cached Medicine Technology:Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements 2Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements 3Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements 4AdvaMed & BioOhio Discuss MedTech Impact on Ohio's Economy, Job Creation 2AdvaMed & BioOhio Discuss MedTech Impact on Ohio's Economy, Job Creation 3
(Date:8/20/2014)... MA (PRWEB) August 20, 2014 Fresh from ... jogging stroller just sprung from the starting blocks. , Urbini, ... studios, has added the Urbini Avi jogger to ... nearly a year, with a look inspired by the latest ... delight fitness-minded parents. , This versatile jogger offers a swift, ...
(Date:8/20/2014)... CA (PRWEB) August 20, 2014 If old ... found a cure for it. With extensive research on HGH ... named ‘MetroMD’ claims to have perfected the art of rubbing ... a brand new younger look with their revolutionary anti-aging hormone ... of the 21st century fountain of youth, the MD of ...
(Date:8/20/2014)... Raleigh, NC (PRWEB) August 20, 2014 Doctors ... a way to wipe out mesothelioma in laboratory mice by ... Mesothelioma has just posted details of the study on its ... , Scientists with Hong Kong University’s AIDS Institute of ... death protein 1” or PD-1. By altering DNA, the vaccine ...
(Date:8/20/2014)... August 20, 2014 The National ... five-year, $1.24 million Science Education Partnership Award (SEPA) ... support NAHN’s collaborative project with the Hispanic Communications ... Careers. , This collaborative NIH R25 program has ... and linguistic diversity among health professionals by recruiting ...
(Date:8/20/2014)... 20, 2014 Parents and kids across ... from summer months means buying textbooks and arranging after ... often a forgotten part of the annual re-commitment to ... the American Psychological Association, 27% of students say they ... (45%) say they are stressed by school pressures. The ...
Breaking Medicine News(10 mins):Health News:Urbini Breezes Through Summer with New Jogging Stroller 2Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2Health News:New Research Study Finds Vaccine Stops Mesothelioma in Lab Mice, According to Surviving Mesothelioma Website 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3Health News:Five Easy Steps to Help Your Child Manage Back-to-school Stress 2Health News:Five Easy Steps to Help Your Child Manage Back-to-school Stress 3
... March 17 Baxa Corporation announces,the latest ... and Resources),Center course offerings. Safe Handling and ... nurses, pharmacists and physicians that prepare,handle or ... hands-on,experience with regulatory compliance and industry best ...
... Data could lead to new drugs to check vascular ... MONDAY, March 17 (HealthDay News) -- Researchers have pinpointed ... proliferation and leakiness behind most cases of blindness in ... of Utah study suggests a new therapeutic target for ...
... CARMEL, Ind., March 17 Conseco, Inc. (NYSE:,CNO) today ... Partners II,L.P. to nominate two of its representatives to ... been reviewing strategic,alternatives and has engaged the investment banking ... CEO Jim Prieur said, "We share with Steel Partners, ...
... March 17 ANSYS, Inc.,(Nasdaq: ANSS ), ... to optimize product development processes, today announced it ... exhibit at the Carnegie Museum of,Natural History in ... the,world to feature scientifically accurate, immersive environments that ...
... Echocardiographic Data Safety Monitoring Board, Review ... SAN DIEGO, March 17 Arena ... that following a planned review by an,independent ... is,continuing BLOOM (Behavioral modification and Lorcaserin for ...
... California public payers now cover Monogram,s Trofile assay, ... Biosciences, Inc. (Nasdaq: MGRM ) today announced ... and,reimbursement for Monogram,s Trofile Assay., Medi-Cal is ... provide essential medical care and services to individuals,or ...
Cached Medicine News:Health News:Baxa Corporation Announces Safe Handling and Preparation of Hazardous Drugs Course Offering at its STAR Center Training Facility 2Health News:Baxa Corporation Announces Safe Handling and Preparation of Hazardous Drugs Course Offering at its STAR Center Training Facility 3Health News:Study Finds Potential Cause of Age-Related Macular Degeneration 2Health News:Study Finds Potential Cause of Age-Related Macular Degeneration 3Health News:ANSYS Sponsors Dinosaurs Exhibit at Carnegie Museum of Natural History 2Health News:ANSYS Sponsors Dinosaurs Exhibit at Carnegie Museum of Natural History 3Health News:Arena Pharmaceuticals' Lorcaserin for Obesity Passes Major Safety Milestone 2Health News:Arena Pharmaceuticals' Lorcaserin for Obesity Passes Major Safety Milestone 3Health News:Arena Pharmaceuticals' Lorcaserin for Obesity Passes Major Safety Milestone 4Health News:Arena Pharmaceuticals' Lorcaserin for Obesity Passes Major Safety Milestone 5Health News:Arena Pharmaceuticals' Lorcaserin for Obesity Passes Major Safety Milestone 6Health News:California Medicaid Establishes Coverage for Trofile(TM) 2Health News:California Medicaid Establishes Coverage for Trofile(TM) 3Health News:California Medicaid Establishes Coverage for Trofile(TM) 4
... your expectations with state of the art ... customized to meet the needs of your ... can be upgraded to grow with you. ... database management, it is easy to see ...
... ultimate flexibility by allowing you to determine ... display. Wall-mount anywhere in the room. Further ... laptop, touch screen tablet, industrial PC, desktop ... multi-function patient tower provides more power and ...
... capabilities combined with ease of use make ... its class. Ideal for office or hospital-based ... for Uroflowmetry, cystometry, leak point pressure, or ... available which make the OM-5 flexible enough ...
... combined with ease of use make the ... class. Ideal for office or hospital-based urodynamics, ... Uroflowmetry, cystometry, leak point pressure, or urethral ... which make the OM-5 flexible enough to ...
Medicine Products: